At What Price Is Canopy (TSX:WEED) Worth Buying?

With the rapid decline of Canopy Growth Corp’s (TSX:WEED)(NYSE:CGC) value, you could buy the weed stock for a song.

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The market value of the one-time pride of the cannabis industry has eroded over the last five months. As of this writing, Canopy Growth’s (TSX:WEED)(NYSE:CGC) market cap is $10.85 billion. If it falls below $10 billion, the company loses its large-market-cap status. If you were to invest in WEED, at what price should you buy it?

Canopy is facing a bumpy ride ahead. The pressure is on for management to maneuver the business, stop the bleeding, and endure the storm. Otherwise, the company would not be able to assume a dominant industry position.

New direction

The partnership with Constellation Brands was supposed to guarantee Canopy’s long-term success. But the alcoholic beverage giant has had enough of the previous CEO’s strategy of giving up profits in favour of massive investments in growth. The fiscal first-quarter net loss of $1.28 billion affirms Constellation’s disgust.

Canopy is struggling to become a sustainable, high-margin, and profitable business. However, Canopy’s interim CEO Mark Zekulin bared a two-pronged approach to achieve the objectives.

He said that Canopy would remain focused on laying the foundation for dominance in an emerging global opportunity. The game plan is to invest in developing intellectual property, build brands, build international reach, and ensure scaled production capability for current and future products.

The second approach is that Canopy would remain fixated on the process of evolving from builders to operators over the remainder of this fiscal year. With Constellation Brands running the show, Canopy is heading to further diversification.

Biggest loser

Canopy’s strategy doesn’t assure investors. Unlike before, people no longer bite whenever cannabis companies disclose plans. A newsflash won’t work to boost the stock anymore, especially if Canopy is the industry’s biggest loser as of August 2019.

Constellation Brands expects to book US$54 million in its second quarter of fiscal 2020 ending on Aug. 31, 2019, because of Canopy. But despite the considerable loss, Canopy’s significant shareholder is confident its high-profile investment will pay off in the future.

Within a month, Canopy’s market value dropped by 27.45% to its current level. The company continues to produce sub-par operating results with cannabis sales remaining flat. An inventory re-balancing led to more sales of low-margin cannabis products. Canopy’s high costs and low margins are red flags.

Canopy won’t be able to create inroads in the international markets until Canada resolves the supply problems. Canopy is also pinning its hope on the U.S. market with the acquisition of Acreage Holdings on a contingency basis. However, cannabis legalization at the federal level would come in about two to five years’ time.

Price forecast

Back in late April, WEED was trading at $69.90, or 55% higher than its current price of $31.18. One month after the firing of Bruce Linton as Canopy’s CEO on July 2, WEED fell by 18% to $43.22. A day after reporting a $1.2 billion quarterly loss, the stock sunk further to $36.41.

WEED is nearing its 52-week low, so don’t bet your marbles yet. You won’t lose any if you wait for the stock to post a new low. More likely, the industry’s bellwether could be the last among cannabis stocks to generate recurring profit.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »